CATALAYER NEWS
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer – Company Announcement - FT.com - Financial Times
Source: Financial Times · 2026-09-04
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer – Company Announcement - FT.com Financial Times
MORE FROM FINANCIAL TIMES
Allianz Global Investors ETF ICAV - Net Asset Value(s) – Company Announcement - Financial Times
2026-09-10
Pictet ICAV - Net Asset Value(s) – Company Announcement - Financial Times
2026-09-10
Nordea ICAV ETF - Net Asset Value(s) – Company Announcement - Financial Times
2026-09-10
Must high bond yields crack stocks? - Financial Times
2026-09-10
AI rewrites the venture capital playbook - Financial Times
2026-09-10
RELATED ON CATALAYER
Mentioned Tickers
$AZN · AstraZenecaRelated Topics
Biotech & FDA NewsRELATED MARKETS
Prediction Markets